A partnership between UC Davis Comprehensive Cancer Center, TargaGenix, and Northeastern University will receive nearly $3 million over five years to study pancreatic ductal adenocarcinoma through an NIH R01 grant.
Cedars-Sinai investigators who previously developed an imaging tool that used artificial intelligence to predict pancreatic cancer are now working to adapt that tool specifically for Black patients, who have disproportionately high rates of the disease.
